Email updates

Keep up to date with the latest news and content from BMC Complementary and Alternative Medicine and BioMed Central.

This article is part of the supplement: Scientific Abstracts Presented at the International Research Congress on Integrative Medicine and Health 2012

Open Access Open Badges Poster presentation

P02.186. CAST (Centella asiatica selected triterpenes): stability, safety, and effect on diabetic neuropathy (DN)

A Soumyanath*, D Dimitrova, G Arnold, H Belding, N Seifer, N Le and J Lou

  • * Corresponding author: A Soumyanath

Author Affiliations

Oregon Health & Science University, Portland, USA

For all author emails, please log on.

BMC Complementary and Alternative Medicine 2012, 12(Suppl 1):P242  doi:10.1186/1472-6882-12-S1-P242

The electronic version of this article is the complete one and can be found online at:

Published:12 June 2012

© 2012 Soumyanath et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The Ayurvedic nerve tonic herb Centella asiatica demonstrates potential neuro-regenerative properties in in vitro and in vivo models. The aims of the present study were to evaluate the safety and therapeutic effects of CAST (Indena®, Milan, Italy) in humans with DN, while monitoring the stability of CAST during the trial period.


The stability of CAST was monitored throughout the study using reversed phase high performance liquid chromatography. CAST or placebo capsules were administered to 33 DN subjects, in a randomized double-blind, placebo-controlled study. The dose of CAST was escalated from 60 mg to 240 mg/day over the first 12 weeks, followed by a stable dose of 240 mg/day for the remaining 40 weeks. The primary outcome was total symptom score (TSS), while secondary outcomes were nerve conduction studies, neurological disability score (NDS) and qualitative sensory testing (QST).


CAST was stable (<10% change from starting values) at room temperature for the duration of the study. At baseline, there was no difference in outcome measures between treatment (n=15, 3F/12M) and placebo (n=18, 6F/12M) groups (TSS: 8.4±2.9 vs 8.3±2.5; combined sensory nerve action potential amplitude of sural and radial (SNAP): 18.8±8.9 vs 17.7±15.4 μV). At week 52, subjects in the treatment group had significantly lower TSS scores (6.4±0.4 vs 7.5±0.4, p<0.05) and higher SNAP (20.3±2.4 vs 14.8±2.2 μV, p<0.05) than the placebo group. Other outcome measures did not differ significantly between the two groups.


CAST was stable and well tolerated by subjects at up to 240 mg per day. Compared to placebo, CAST significantly improved subjective DN symptoms (TSS score) and prevented deterioration in an objective measure of nerve conduction (SNAP). Current treatments for DN provide symptomatic relief rather than ameliorating disease progression. Multicenter trials are clearly warranted to further evaluate the role of CAST as a novel disease-modifying agent for DN.